A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | NYU Langone Health

Go Back to All Clinical Trials

A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Breast Cancer, Colorectal Cancer, Solid Tumor, High Grade Glioma
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Patient has a metastatic solid tumor. 2) Patient is positive for EGFR or HER2 mutations based on DNA genetic testing of either tumor tissue or blood samples. 3) Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

You may not be eligible for this study if the following are true:

1) Patient has primary tumors in central nervous system (CNS) or in brain except for some groups. 2) Patients with the T790M mutation in EGFR. 3) Patients with breast or gastric cancers without eligible HER2 mutations. 4) Patient has received anticancer chemotherapy, biologics, immunotherapy, targeted therapy (including HER2 targeted therapy), curative-intent radiotherapy, or other investigational treatment within 15 days.